近日，药明巨诺（开曼）有限公司（以下简称“药明巨诺”）成功在香港联交所上市，募集资金约23亿港元（约合3亿美元）。方达律师事务所、天元律师事务所、谢尔曼·思特灵律师事务所作为发行人律师参与项目；美国达维律师事务所、通商律师事务所则为承销商提供法律意见。
药明巨诺由中国制药领域龙头企业药明康德和全球细胞免疫治疗领域明星公司Juno Therapeutics, Inc.于2016年共同创立。药明巨诺深耕细胞免疫治疗领域，专注于打造血液癌症及实体瘤开发、制造和商业化突破性细胞免疫疗法的一体化治疗平台。
方达团队牵头合伙人为罗德源；天元团队牵头合伙人为傅思齐、郁岩、杨喻意；谢尔曼·思特灵团队牵头合伙人为Kyungwon (Won) Lee、华一春。
承销商律师方面，通商团队由合伙人王波牵头带领。
Shearman, Davis Polk lead on Chinese cell therapy developer’s $300 mln HK IPO
Shearman & Sterling, Fangda Partners and Tian Yuan Law Firm have advised Chinese cancer cell therapy developer JW Therapeutics on its $300 million IPO in Hong Kong, with Davis Polk & Wardwell and Commerce & Finance Law Offices counselling the joint sponsors and underwriters.
JW Therapeutics is a clinical stage cell therapy platform company, founded by Juno Therapeutics and WuXi AppTec in 2016, and focused on developing, manufacturing and commercialising breakthrough cell-based immunotherapies for hematological cancers and solid tumours.
The listing is the latest in the recent flurry of biotech IPOs in Hong Kong. Other recent issuers in the city include Simcere Pharmaceutical Group, JHBP (CY) Holdings and Everest Medicines.
The Fangda team on this transaction was led by partner Colin Law. The Tian Yuan team was led by partners Fu Siqi, Yu Yan and Yang Yuyi. The Shearman team was led by partners Kyungwon (Won) Lee and Max Hua.
The Commerce & Finance team was led by partner Wang Bo.
To contact the editorial team, please email ALBEditor@thomsonreuters.com.
